Why the Bexsero delay? Novartis holding government to 'ransom,' U.K. says

U.K. Health Secretary Jeremy Hunt

The U.K. and Novartis ($NVS) have been negotiating for months now on a fair price for the Swiss pharma's meningitis B shot, Bexsero, which the country plans to add to its childhood vaccination schedule. So what's the holdup? If you ask U.K. Health Secretary Jeremy Hunt's team, it's all on the Basel-based drugmaker, which it says is holding the government "to ransom." More from FierceVaccines